We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

London — GlaxoSmithKline (GSK), Britain’s biggest drug maker, faces more top management change with chief financial officer Simon Dingemans retiring in 2019. The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. As Dingemans’s departure is voluntary he will not receive a severance payment. The group said it planned to look both internally and externally to identify a successor. The departure provides a further opportunity for CEO Emma Walmsley to stamp her imprint on the group as she tries to increase sales and improve productivity in the core pharmaceuticals division. Walmsley, who took over in April 2017, has already appointed a new head of pharmaceuticals in Luke Miels and a new head of drug research in Hal Barron, as well as making Karenann Terrell the head of digital operations, an area within Dingemans’s orbit. In his time at GSK, Dingemans has helped oversee two transformational deals with Nov...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.